Investors & Media
News
SAGE Therapeutics Reports Second Quarter 2014 Financial Results
Successfully Completed Initial Public Offering and Reported Preliminary Results for SAGE-547 in Super-Refractory Status Epilepticus
"This has been a great year for SAGE in several areas," stated
Recent Business Highlights
-
Completion of Initial Public Offering (IPO): On
July 23, 2014 , SAGE announced that it had completed its IPO of common stock, raising net proceeds of$94.0 million , after deducting underwriting discounts and commissions and estimated offering expenses. -
Granted Fast Track Designation: In July, SAGE announced that
the
FDA had granted fast track designation for the SAGE-547 development program. Fast track designation is intended to facilitate the review of drug candidates that are meant to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. - Reported Preliminary Phase 1/2 Clinical Data on SAGE-547: SAGE reported preliminary results from its ongoing Phase 1/2 clinical trial of SAGE-547 in patients with SRSE. These data indicated that the first four patients enrolled in the clinical trial met the key efficacy endpoint, in that each was successfully weaned off his or her anesthetic agent while SAGE-547 was being administered. In addition, these data have not shown any reported drug-related serious adverse events in these four patients.
-
Granted Orphan Drug Designation: In March, SAGE announced that
it had been granted orphan drug designation for SAGE-547 for the
treatment of status epilepticus, a life-threatening seizure condition,
by the
FDA . -
Strengthened Leadership Team: SAGE strengthened its leadership
team with the addition of
Howard Pien andJames Frates to its Board of Directors and the appointment ofThomas Anderson as chief commercial strategy officer.
Financial Results
-
Cash Position: Cash, cash equivalents and marketable securities
as of
June 30, 2014 , were$49.1 million compared with$8.1 million atDecember 31, 2013 . The increase is primarily driven by proceeds from a$38 million Series C Preferred Stock financing completed inMarch 2014 . Proceeds from the IPO will be recognized in the third quarter of 2014. -
R&D Expenses: Research and development expenses were
$4.4 million in the second quarter of 2014 compared to$3.9 million in the second quarter of 2013. The increase in R&D expenses was primarily due to increased spending on clinical activities as SAGE-547 entered Phase 1/2 development inMarch 2014 and an increase in employee-related spending to support the growth in SAGE's R&D activities, partially offset by decreased expenses associated with other R&D programs. -
G&A Expenses: General and administrative expenses were
$1.8 million in the second quarter of 2014 compared to$0.8 million for the second quarter of 2013. The increase in G&A expenses was largely due to personnel related costs with an increase in personnel to support the activities associated with becoming a public company. -
Net Loss: Net loss was
$6.2 million for the second quarter of 2014 compared to net loss of$4.7 million for the second quarter of 2013.
About
Forward-Looking Statement
This release contains forward-looking statements and information. The
use of words such as "may," "might," "will," "should," "expect," "plan,"
"anticipate," "believe," "estimate," "project," "intend," "future,"
"potential," or "continue," and other similar expressions are intended
to identify forward looking statements. For example SAGE's future
expectations, plans and prospects, including without limitation, SAGE's
expectations regarding the potential safety, pharmacological effect and
efficacy of SAGE-547 as a treatment for SRSE, the expected development
pathway for its other product candidates and its expectations with
respect to the timing and success of its clinical trials, constitute
forward-looking statements for the purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of 1995
and other federal securities laws. In particular it should be noted that
the initial data reported from the ongoing Phase 1/2 clinical trial of
SAGE-547 are preliminary in nature and that the SAGE-547 clinical trial
has not been completed. The preliminary data may change as additional
data is released and such preliminary data may not be repeated or
observed in ongoing or future studies involving SAGE-547 or our other
product candidates. Actual results may differ materially from those
indicated by these forward-looking statements as a result of various
important factors, including, without limitation, SAGE's ability to
successfully demonstrate the efficacy and safety of its product
candidates, the pre-clinical and clinical results for its product
candidates, which may not support further development of product
candidates, actions of regulatory agencies, which may affect the
initiation, timing and progress of clinical trials, obtaining,
maintaining and protecting intellectual property, SAGE's ability to
enforce its patents against infringers and defend its patent portfolio
against challenges from third parties, competition from others
developing products for similar uses, SAGE's ability to manage operating
expenses, SAGE's ability to obtain additional funding to support its
business activities and establish and maintain strategic business
alliances and new business initiatives, SAGE's dependence on third
parties for development, manufacture, marketing, sales and distribution
of products, the outcome of litigation, and unexpected expenditures, as
well as those risks more fully discussed in the section entitled "Risk
Factors" in the final prospectus related to SAGE's initial public
offering filed with the
Condensed Statement of Operations (in thousands, except share and per share data) (Unaudited) |
||||||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||||||
2014 | 2013 | 2014 | 2013 | |||||||||||||||||
Operating expenses: | ||||||||||||||||||||
Research and development | $ | 4,381 | $ | 3,854 | $ | 8,554 | $ | 6,437 | ||||||||||||
General and administrative | 1,807 | 801 | 3,424 | 1,607 | ||||||||||||||||
Total operating expenses | 6,188 | 4,655 | 11,978 | 8,044 | ||||||||||||||||
Loss from operations | (6,188) | (4,655) | (11,978) | (8,044) | ||||||||||||||||
Interest income (expense), net | 1 | - | 1 | - | ||||||||||||||||
Other income (expense), net | (5) | - | (5) | - | ||||||||||||||||
Net loss and comprehensive loss | (6,192) | (4,655) | (11,982) | (8,044) | ||||||||||||||||
Accretion of redeemable convertible preferred stock to redemption value |
(1,577) | - | (1,903) | - | ||||||||||||||||
Net loss attributable to common stockholders | $ | (7,769) | $ | (4,655) | $ | (13,885) | $ | (8,044) | ||||||||||||
Net loss per share attributable to common stockholders—basic and diluted |
$ |
(4.57) |
|
$ | (3.18) | $ | (8.28) | $ | (5.58) | |||||||||||
Weighted average number of common shares used in net loss per share attributable to common stockholders—basic and diluted |
1,700,517 |
|
1,464,419 | 1,676,864 | 1,442,774 | |||||||||||||||
Condensed Balance Sheets (in thousands, except share and per share data) (Unaudited) |
||||||||||||||||
2014 |
2013 |
|||||||||||||||
Assets | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 49,127 | $ | 8,066 | ||||||||||||
Prepaid expenses and other current assets | 2,416 | 341 | ||||||||||||||
Total current assets | 51,543 | 8,407 | ||||||||||||||
Property and equipment, net | 69 | 86 | ||||||||||||||
Restricted cash | 39 | 39 | ||||||||||||||
Total assets | $ | 51,651 | $ | 8,532 | ||||||||||||
Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable | $ | 1,862 | $ | 1,988 | ||||||||||||
Accrued expenses | 2,069 | 327 | ||||||||||||||
Total current liabilities | 3,931 | 2,315 | ||||||||||||||
Other liabilities: | 40 | 44 | ||||||||||||||
Total liabilities | 3,971 | 2,359 | ||||||||||||||
Redeemable convertible preferred stock (Series A, B and C),
|
92,472 | 37,709 | ||||||||||||||
Stockholders' deficit: | ||||||||||||||||
Common stock, |
- | - | ||||||||||||||
Additional paid-in capital | - | 139 | ||||||||||||||
Accumulated deficit | (44,792 | ) | (31,675 | ) | ||||||||||||
Total stockholders deficit | (44,792 | ) | (31,536 | ) | ||||||||||||
Total liabilities, redeemable convertible preferred stock and stockholders' deficit |
$ | 51,651 | $ | 8,532 | ||||||||||||
Media Contact:
dan@purecommunicationsinc.com
or
Investor
Contact:
monique@purecommunicationsinc.com
Source:
News Provided by Acquire Media